TOP-N53
Digital Ulcers in Systemic Sclerosis
Key Facts
About Topadur Pharma
Topadur Pharma is a private, clinical-stage biotech targeting age-related diseases driven by microvascular dysfunction. Its core asset is the DualTOP® platform, which employs a dual mechanism to induce vasodilation and angiogenesis for localized tissue regeneration. The pipeline features two lead programs, TOP-N53 for digital ulcers and diabetic foot ulcers and TOP-M119 for androgenetic alopecia, both advancing through Phase 2. The company follows a capital-efficient, partnership-driven strategy to advance its assets through proof-of-concept trials.
View full company profileAbout Topadur Pharma
Topadur Pharma is a private, clinical-stage biotech targeting age-related diseases driven by microvascular dysfunction. Its core asset is the DualTOP® platform, which employs a dual mechanism to induce vasodilation and angiogenesis for localized tissue regeneration. The pipeline features two lead programs, TOP-N53 for digital ulcers and diabetic foot ulcers and TOP-M119 for androgenetic alopecia, both advancing through Phase 2. The company follows a capital-efficient, partnership-driven strategy to advance its assets through proof-of-concept trials.
View full company profile